These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
196 related articles for article (PubMed ID: 37573025)
1. Clinical significance of risk-reducing salpingo-oophorectomy in patients with BRCA1/2 mutation. Abay M; Ozgen L; Yalcin Y; Ozerkan K J Gynecol Obstet Hum Reprod; 2023 Oct; 52(8):102642. PubMed ID: 37573025 [TBL] [Abstract][Full Text] [Related]
2. Efficacy of risk-reducing salpingo-oophorectomy in BRCA1-2 variants and clinical outcomes of follow-up in patients with isolated serous tubal intraepithelial carcinoma (STIC). Saccardi C; Zovato S; Spagnol G; Bonaldo G; Marchetti M; Alessandrini L; Tognazzo S; Guerriero A; Vitagliano A; Laganà AS; Noventa M Gynecol Oncol; 2021 Nov; 163(2):364-370. PubMed ID: 34465478 [TBL] [Abstract][Full Text] [Related]
3. Development of Peritoneal Carcinoma in women diagnosed with Serous Tubal Intraepithelial Carcinoma (STIC) following Risk-Reducing Salpingo-Oophorectomy (RRSO). Stanciu PI; Ind TEJ; Barton DPJ; Butler JB; Vroobel KM; Attygalle AD; Nobbenhuis MAE J Ovarian Res; 2019 May; 12(1):50. PubMed ID: 31128592 [TBL] [Abstract][Full Text] [Related]
4. Retrospective study of a 16 year cohort of BRCA1 and BRCA2 carriers presenting for RRSO: Prevalence of invasive and in-situ carcinoma, with follow-up. Blok F; Dasgupta S; Dinjens WNM; Roes EM; van Beekhuizen HJ; Ewing-Graham PC Gynecol Oncol; 2019 May; 153(2):326-334. PubMed ID: 30894273 [TBL] [Abstract][Full Text] [Related]
5. Pathological findings and long-term prognosis in Korean BRCA1/2 mutation carriers undergoing risk-reducing salpingo-oophorectomy. Kang OJ; Lee SW; Kim JH; Park JY; Suh DS; Kim DY; Kim JH; Kim YM; Kim YT Int J Gynecol Cancer; 2023 Nov; 33(11):1743-1749. PubMed ID: 37541685 [TBL] [Abstract][Full Text] [Related]
6. Does serous tubal intraepithelial carcinoma (STIC) metastasize? The clonal relationship between STIC and subsequent high-grade serous carcinoma in BRCA1/2 mutation carriers several years after risk-reducing salpingo-oophorectomy. van den Berg CB; Dasgupta S; Ewing-Graham PC; Bart J; Bulten J; Gaarenstroom KN; de Hullu JA; Mom CH; Mourits MJE; Steenbeek MP; van Marion R; van Beekhuizen HJ Gynecol Oncol; 2024 Aug; 187():113-119. PubMed ID: 38759517 [TBL] [Abstract][Full Text] [Related]
7. Pathological findings following risk-reducing salpingo-oophorectomy in BRCA mutation carriers: A systematic review and meta-analysis. Cheng A; Li L; Wu M; Lang J Eur J Surg Oncol; 2020 Jan; 46(1):139-147. PubMed ID: 31521389 [TBL] [Abstract][Full Text] [Related]
8. The Role of Routine Peritoneal and Omental Biopsies at Risk-Reducing Salpingo-Oophorectomy. Miller H; Pipkin LS; Tung C; Hall TR; Masand RP; Anderson ML J Minim Invasive Gynecol; 2017; 24(5):772-776. PubMed ID: 28285055 [TBL] [Abstract][Full Text] [Related]
9. The prevalence of occult ovarian cancer in the series of 155 consequently operated high risk asymptomatic patients - Slovenian population based study. Gornjec A; Merlo S; Novakovic S; Stegel V; Gazic B; Perhavec A; Blatnik A; Krajc M Radiol Oncol; 2020 May; 54(2):180-186. PubMed ID: 32463390 [TBL] [Abstract][Full Text] [Related]
13. Risk reducing surgery with peritoneal staging in BRCA1-2 mutation carriers. A prospective study. Marchetti C; Arcieri M; Vertechy L; Ergasti R; Russo G; Zannoni GF; Minucci A; Ercoli A; Scambia G; Fagotti A Eur J Surg Oncol; 2022 Dec; 48(12):2539-2544. PubMed ID: 35871032 [TBL] [Abstract][Full Text] [Related]
14. Value of adjuvant chemotherapy and informed microscopic examination for occult gynecologic cancer detected upon risk-reducing salpingo-oophorectomy after chemotherapy for BRCA1/2-associated breast cancer: a case report. Kuji S; Kondo H; Ohara T; Deura I; Tozawa-Ono A; Migita O; Kawamoto H; Tsugawa K; Chosokabe M; Koike J; Maeda I; Suzuki N Jpn J Clin Oncol; 2021 Mar; 51(3):492-497. PubMed ID: 33377156 [TBL] [Abstract][Full Text] [Related]
15. Risk of Peritoneal Carcinomatosis After Risk-Reducing Salpingo-Oophorectomy: A Systematic Review and Individual Patient Data Meta-Analysis. Steenbeek MP; van Bommel MHD; Bulten J; Hulsmann JA; Bogaerts J; Garcia C; Cun HT; Lu KH; van Beekhuizen HJ; Minig L; Gaarenstroom KN; Nobbenhuis M; Krajc M; Rudaitis V; Norquist BM; Swisher EM; Mourits MJE; Massuger LFAG; Hoogerbrugge N; Hermens RPMG; IntHout J; de Hullu JA J Clin Oncol; 2022 Jun; 40(17):1879-1891. PubMed ID: 35302882 [TBL] [Abstract][Full Text] [Related]
16. Prophylactic risk-reducing salpingo-oophorectomy in BRCA mutation carriers: what is going on in a region of northern Italy? Grandi G; Perrone AM; Perrone A; Mandato VD; Comerci G; Sammarini M; Merisio C; Amadori A; Stefanetti M; Martinello R; Facchinetti F; De Iaco P; Maturitas; 2021 Jan; 143():59-64. PubMed ID: 33308637 [TBL] [Abstract][Full Text] [Related]
17. Outcome and Prognostic Impact of Surgical Staging in Serous Tubal Intraepithelial Carcinoma: A Cohort Study and Systematic Review. Van der Hoeven NMA; Van Wijk K; Bonfrer SE; Beltman JJ; Louwe LA; De Kroon CD; Van Asperen CJ; Gaarenstroom KN Clin Oncol (R Coll Radiol); 2018 Aug; 30(8):463-471. PubMed ID: 29691126 [TBL] [Abstract][Full Text] [Related]
18. Occult and subsequent cancer incidence following risk-reducing surgery in BRCA mutation carriers. Zakhour M; Danovitch Y; Lester J; Rimel BJ; Walsh CS; Li AJ; Karlan BY; Cass I Gynecol Oncol; 2016 Nov; 143(2):231-235. PubMed ID: 27623252 [TBL] [Abstract][Full Text] [Related]
19. Quantitative analysis of γ-H2AX and p53 nuclear expression levels in ovarian and fallopian tube epithelium from risk-reducing salpingo-oophorectomies in BRCA1 and BRCA2 mutation carriers. Staff S; Tolonen T; Laasanen SL; Mecklin JP; Isola J; Mäenpää J Int J Gynecol Pathol; 2014 May; 33(3):309-16. PubMed ID: 24681744 [TBL] [Abstract][Full Text] [Related]
20. Pathologic findings and clinical outcomes in women undergoing risk-reducing surgery to prevent ovarian and fallopian tube carcinoma: A large prospective single institution experience. Rush SK; Swisher EM; Garcia RL; Pennington KP; Agnew KJ; Kilgore MR; Norquist BM Gynecol Oncol; 2020 May; 157(2):514-520. PubMed ID: 32199636 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]